StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) income statement

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$12.00+0.69 (+6.10%)

Close on Nov 18, 2026Market cap $237.93MP/E –Yield –

Keros Therapeutics, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
-698.0%
Net margin
-572.1%
Return on equity, FY2025
19.9%

Financial strength

Current ratio
21.96
Debt to equity
–
Debt to assets
–
Cash to current liabilities
2119.7%

Valuation

P/E ratio
–
Price to sales
16.37
Price to book
0.91
Dividend yield
–

See a number that looks wrong?